What's Happening?
Mission Bio has announced the launch of its Tapestri® Single-Cell Targeted DNA + RNA Assay, a pioneering platform that measures genotypic and transcriptional readouts within the same cell. This assay is designed
to empower oncology and translational researchers by directly linking mutations to their functional consequences, thereby uncovering mechanisms driving resistance, relapse, and therapeutic response. The assay aims to advance precision medicine by enabling more effective therapeutic innovation. It unifies genotyping and gene expression in the same cell, eliminating the need for multi-platform data integration and heavy computational alignment. This development is significant for mapping clonal architecture in blood cancers and understanding how mutations influence transcriptional states in diseases like acute myeloid leukemia and myelodysplastic syndromes.
Why It's Important?
The introduction of the Tapestri® Single-Cell Targeted DNA + RNA Assay marks a significant advancement in personalized medicine and targeted therapies. By providing a unified platform for genotyping and gene expression analysis, researchers can gain deeper insights into the biological complexity of diseases at the single-cell level. This can lead to more tailored and effective treatment strategies, particularly in the field of cancer research. The assay's ability to link genetic changes with their functional impact is crucial for understanding therapeutic resistance and response, potentially improving patient outcomes and advancing the development of next-generation medical treatments.
What's Next?
Mission Bio plans to feature the assay in demonstrations at the American Society of Hematology (ASH) Annual Meeting 2025, highlighting its use in therapy resistance, relapse modeling, and preclinical quality assessment. The assay is currently offered for research use only, and its integration into existing Tapestri chemistry and instrumentation allows current users to add RNA capability without re-validation of laboratory infrastructure or data pipelines. This launch continues Mission Bio's leadership in single-cell multi-omics, with the potential to set new analytical standards for translational hematology and engineered cell development.
